Multiple Myeloma Yields to CD38 Inhibitors.
[No authors listed]. Cancer Discov. 2015 Jan 16. [Epub ahead of print].
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.
Atrash S et al. Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93.
Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
Mangiacavalli S et al. Leuk Lymphoma. 2015 Jan 14:1-2. [Epub ahead of print].
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ et al. Am J Hematol. 2015 Jan;90(1):42-9. doi: 10.1002/ajh.23868.